Quantcast
Home > Quotes > EDIT

Editas Medicine, Inc. Common Stock (EDIT) Quote & Summary Data

EDIT 
$28.45
*  
0.49
1.69%
Get EDIT Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading EDIT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
44
Today's High / Low
$ 29.35 / $ 28.25
Share Volume
365,437
50 Day Avg. Daily Volume
694,448
Previous Close
$ 28.94
52 Week High / Low
$ 45.02 / $ 23.829
Market Cap
1,360,199,906
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.65
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.03

Intraday Chart

News for EDIT

Shares Traded

Share Volume:
365,437
50 Day Avg. Daily Volume:
694,448

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.65

Trading Range

The current last sale of $28.45 is 19.39% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 29.35 $ 45.02
 Low: $ 28.25 $ 23.829

ETFs with EDIT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
6.61% ARK Genomic Revolution Multi-Sector ETF (ARKG) -3.03 (-9.79%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a leading genome editing company dedicated to developing transformative genomic medicines with the aim to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome, and harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, genome editing. We believe this progress sets the stage for us to create unprecedented medicines with the potential to have a durable benefit for patients. At Editas Medicine, our core capability in genome editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) with which we can create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of this science into a broad class of medicines to help people living with serious diseases around the world.  ... More ...  


Risk Grade

Where does EDIT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 28.59
Open Date:
Dec. 14, 2018
Close Price:
$ 28.45
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info